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Objectives. The aim of the study was to analyse the cytokine memory of T-cells derived from systemic lupus erythematosus (SLE) patients and healthy donors enriched for autoantigen-specific T-cells by in vitro stimulation with SmD1 , a common autoantigen in SLE. Methods. Autoreactive CD3þ T-cells derived from 37 SLE patients and 14 healthy donors were enriched by repetitive ex vivo stimulation of peripheral blood mononuclear cells (PBMCs) with SmD1 . For control, PBMCs were stimulated only with interleukin-2 (IL-2). After two rounds of antigenic stimulation, cultures were stimulated with PMA/ionomycin to probe the cytokine memory by intracellular cytokine staining. Frequencies of cytokine-expressing T-cells were analysed and, in SLE patients, compared with disease activities and autoantibody levels.
Results. Comparing the cytokine memory in the cultures, SLE patients displayed higher frequencies of tumour necrosis factor-(TNF-)þ T-cells than healthy donors and the frequencies correlated with disease activity. Frequencies of SmD1 -specific TNF-þ T-cells and of memory T-cells expressing interferon-(IFN-) correlated with serum anti-dsDNA antibody levels. The frequencies of IL-10 expressing SmD1
Introduction
In systemic lupus erythematosus (SLE), the increased number of activated and affinity-maturated T-cells as well as the presence of autoreactive T-cells suggests an impaired T-cell effector function that seems to be restricted to a distinct panel of autoantigens [1] . The impaired effector function is usually best exemplified by the pattern of cytokines produced [2] . Therefore, characterization of T-cell cytokine expression, especially of autoantigen-specific T-cells, is central to understand T-cell help in the etiopathogenesis of lupus.
T-cell cytokines are involved in the control of B-and T-cell interaction and, therefore, are target candidates as regulators of pathogenicity in SLE. Interferon-(IFN-) stimulates B-cells [3, 4] , induces B-and plasma-cell migration into the inflamed tissue [5] and plays a pivotal role in directing cell-mediated immune responses. The increased expression of IFN-in autoreactive T-cell clones indicates a role for IFN-þ T-cells in lupus pathogenesis [4] . Interleukin-4 (IL-4), termed 'B-cell growth factor', also induces B-cell migration [6] and class switch to the immunoglobulin (Ig) isotypes G1/G4 over-represented in SLE [7, 8] . IL-10 induces differentiation of B-cell blasts into plasma cells and also participates in the control of isotype switching towards IgG1 and IgG3 [8] isotypes also over-represented in SLE [9] .
Furthermore, IL-10 has a regulatory function in lupus, (summarized in [10, 11] ) especially when produced by T-cells, and recently, autoantigen-specific IL-10 expressing T-cells were shown to decrease anti-dsDNA antibody generation in vitro [12] . Tumour necrosis factor-(TNF-) is an important proinflammatory cytokine in lupus and other autoimmune diseases [13] . Furthermore, it is a survival factor for plasma cells [14, 15] .
Naive and central memory T-cells do not produce effector cytokines except IL-2. Upon primary activation, naive T-cells become instructed for expression of cytokines. Repetitive stimulations with the corresponding antigen result in a cytokine memory with a faster recall expression of previously instructed cytokines without the requirement of the original instructing signal. This allows a stable effector function [16, 17] . Therefore, T-cells expressing effector cytokines such as IFN-, IL-4, IL-10 and TNF-exhibit effector/memory cells previously instructed by antigens or, in SLE, by autoantigens.
Studying the T-cell cytokine memory among all freshly isolated memory Th cells, most authors have not found any differences between healthy donors and lupus patients [18] [19] [20] . This is probably related to the low frequencies of autoreactive T-cells, which is considered to be <1 per 10 5 T-cells [21, 22] . Furthermore, the missing differences in the T-cell cytokine memory may reflect the heterogeneity of the patients, or the varying balance between different autoreactive T-cell subsets as defined by their cytokine expression during flares and remissions in SLE. In the present study, we attempted to analyse the cytokine memory by a novel approach. We cultured peripheral blood mononuclear cells (PBMCs) over an extended period of time to enrich T-cells specific for autoantigens present in cell cultures as well as for the SmD1 83-119 autoantigenic peptide. Cultures were finally stimulated with PMA/ionomycin to circumvent possible unresponsiveness to physiological T Cell Receptor (TCR) triggering due to extended culturing and repeated restimulation. The T-cell cytokine memory was correlated with clinical findings and autoantibody concentration in the culture supernatants.
Material and methods

Patients
This study was approved by the Ethics Committee of the ChariteÚ niversity Hospital, and is in compliance with the Helsinki Declaration. Blood samples were obtained, after written consent from 37 patients with SLE and 14 healthy donors. Patients fulfilled the American Congress of Rheumatology (ACR) classification criteria for SLE [23] . Most of the patients received immunosuppressive drugs (14 received azathioprine, three cyclophosphamide, four mycophenolate, six hydroxychloroquine, two methotrexate, one leflunomide, one ciclosporin-A, and three patients had a combination of two different immunosuppressive drugs). Two patients received steroids in a dosage >10 mg/day.
The disease activity was measured by SLE Disease Activity Index (SLEDAI) as described elsewhere [24] . Three patients were tested twice at 6-month intervals; one of them with different disease activity, the others remained stable.
Antigen
The SmD1 83-119 peptide (VEPKVKKREAVAGRGRGRGRG RGRGRG-RGRGGPRR) was synthesized as free peptide according to the protocol described by Atherton [25] and purified by a reverse phase chromatography (C18 Vydac column).
Isolation of PBMCs and culture conditions. Approximately 40 ml of venous blood were collected using heparinized S-monovettes (Sarstedt, Nu¨mbrecht, Germany) from SLE patients and healthy donors.
PBMCs were isolated by Ficoll Paque TM PLUS (Amersham Pharmacia Biotech AB, Sweden) density centrifugation, washed twice in Phosphate Buffer Saline (PBS)/Bovine Serum Albumine (BSA) and split: One fraction was suspended in growth medium [Roswell Park Memorial Institute (RPMI) 1640 (all supplements 2 mM L-glutamine, PAA Laboratories, Coelbe, Germany)], 5% heat inactivated human AB serum (PAA, Austria), 0.3 mg/ml glutamine, 50 mM 2-mercaptoethanol (GIBCO Brl, Paisley, UK), 100 U/ml penicillin, 0.1 mg/ml streptomycin (glutamine; PAA Laboratories, Coelbe, Germany) and cultured at 378C and 5% CO 2 . The other fraction was resuspended in chilled freezing medium (70% RPMI 1640, 20% fetal bovine serum, 10% DiMethyl SulfOxide (DMSO)) at the concentrations of approximately 10 Â 10 6 cells/ml and immediately frozen to À708C. At day 3, one portion of the cultured cells received 10 g/ml of the SmD1-peptide, the other portion did not receive any. At day 7, both cultures received 5 U/ml of recombinant (r)IL-2 (Strathmann Biotec AG, Hamburg, Germany). At day 11, the frozen cells were quickly thawed by adding growth medium at room temperature and washed in a high surplus of growth medium. These cells were -irradiated (30 Gy, 10 min) and added as autologous feeder cells to the respective cultures. In addition, 10 g/ml of the SmD1-peptide was given only to the culture previously stimulated with the SmD1 83-119 peptide. At day 18, 5 U/ml of rIL-2 were added to the cultures. Some days later (median at day 22), supernatants of the culture pairs (with and without SmD1 stimulation) were harvested and cells were restimulated with PMA (10 ng/ml) and ionomycin (250 ng/ml) for 6 h. After 3 h, 10 g/ml brefeldin A was added to the cells.
The cells were harvested, washed in PBS and fixed in 2% paraformaldehyde for 20 min at room temperature. After washing with PBS/BSA, the cells were stored in PBS/BSA/acid at 48C overnight. The variability of the used culture system was controlled using PBMCs from healthy donors, demonstrating reproducible results in parallel cultures of cells from the same donor (no outliner values, S.D. comprising 9-54% of the mean value depending on the produced cytokine).
Intracellular cytokine staining and flowcytometric analysis. The cells were first subjected to anti-CD3-Biotin and then to streptavidin-Peridinin-chlorophyll-protein complex (PerCP) (PharMingen), then divided into two groups. One group was stained with anti-IFN--Fluorescein IsoThioCyanate (FITC), anti-IL-4-Phycoerythrin (PE) and anti-IL-10-Cy5, the other group with anti-TNF--FITC, anti-IL-2-PE and anti-IL-4-Cy5. 16 cultures derived from 5 SLE patients were also stained for Cluster of Differentiation (CD)25 (anti-CD25-FITC, PharMingen, San Diego, CA, USA). For intracellular and surface staining, the following monoclonal antibodies (all from PharMingen) were used according to the manufacturer's instructions: IFN--FITC (clone N748A and clone 4SB3),
Intracellular staining was performed in PBS/BSA/acid containing 0.5% saponin. All cells were blocked with 10% polyclonal human IgG (Flebogamma, Grifols, Langen, Germany) in a total of 50-70 l staining volume. The incubation time for surface staining was 10 min, and 15 min for intracellular staining. Samples were analysed by a 4-colour-analysis using Fluorescence Activated Cell Sorting (FACS). Calibur flow cytometer (Becton Dickinson) and FACS-Express software, version 2.0.
Serum anti-SmD1 83-119 peptide antibodies were detected by enzyme-linked immunosorbent assay (ELISA) as described [26] . Reactivity of a standard serum at a dilution of 1:100 was defined as 10 000 arbitrary units (AU). Supernatants were diluted 1:2, sera were analysed at dilution 1:100. Serum reactivity above 123 AU was defined as positive as described before [26] .
Anti-dsDNA antibodies were detected by ELISA as described previously [27] . Serum were tested at dilution 1:100, supernatants at dilution 1:2. Serum levels above 6 mg/ml were defined as positive.
Statistics. Graphpad Prism 3.0 was used for statistical analysis. The frequencies of T-cells expressing cytokines showed a skewed distribution. Therefore, Mann-Whitney U-test was used to compare cytokine expression in different culture conditions. Linear regression was used to compare disease activity and autoantibody levels with cytokine expression or ratios of cytokine expression. Wilcoxon matched pair test as well as paired t-test was used to compare the frequency of CD25þ T-cells in cultures with and without SmD1 83-119 . P-values <0.05 were defined as significantly independent from the R 2 values. Proinflammatory Th cytokine memory correlates to disease activity in SLE patients. To analyse a possible role of memory T-cells expressing one of the investigated cytokine on disease activity, the frequencies of memory/effector T-cells positive for the different cytokines were compared with the disease activity in the corresponding SLE patient.
Results
SLE patients reveal higher frequencies of TNF--expressing memory T-cells
In both cultures, with and without SmD1 83-119 , the frequency of TNF-expressing T-cells correlated with disease activity classified according to SLEDAI (P ¼ 0.027 for the medium control, P ¼ 0.021 for the SmD1 83-119 culture). Patients with active disease showed an increased cytokine memory for TNFcompared with inactive patients (Fig. 2A) . Higher frequencies of IL-10 memory T-cells were associated with lower disease activity in both cultures (P ¼ 0.039 for the medium control, P ¼ 0.032 for 83-119 peptide (P ¼ 0.042 and P ¼ 0.003, respectively). The increase in the frequencies of memory/effector T-cells expressing proinflammatory cytokines and the decrease in the frequency of IL-10-expressing T-cells during active disease were also supported by a 6-month follow-up investigation of one SLE patient suffering from a lupus flare reflected by an increase in SLEDAI from 4 to 9 (Fig. 3) . In this patient, increased frequencies of IFN-þCD3þ T-cells (from 2.9 to 4.8%), of TNFþ (from 3.4 to 4.5%) and of IL-2þ T-cell (from 3.6 to 12%) were detected as well as increased frequencies of IL-4þ T-cells (from 0.4 to 1.7%). In contrast, the frequency of IL-10 expression slightly decreased when active disease was compared with inactive disease (from 0.55 to 0.34%, Fig. 3 ). Another lupus patient with long-term clinical remission showed stable, but very low frequencies of cytokine-expressing T-cells. Table 1) . However, all cultures stimulated with SmD1 83-119 revealed increased frequencies of CD25þ activated T-cells when compared with the medium control (P ¼ 0.008, Fig. 4) .
Comparing the cytokine memory of CD3þ T-cells from SLE patients and healthy donors, 57% of the ex vivo stimulated cultures from healthy donors reacted to 83-119 -specific T-cells, the relative increase in frequencies of SmD1 83-119 -specific memory T-cells expressing one of the investigated cytokines was compared with the serum autoantibody levels and disease activity in the corresponding lupus donors.
The increase in frequencies of IFN-expressing Th cells in the cultures after expansion of SmD1 83-119 -specific T-cells (in%) correlated with serum anti-Sm and anti-dsDNA antibody levels (P ¼ 0.003 and P ¼ 0.016, respectively, Fig. 5A and B) . The higher the increase in SmD1 83-119 -specific T-cells expressing IFN-, the higher were the corresponding serum antibody concentrations. The increase in frequencies of memory Th cells expressing TNFupon SmD1 83-119 stimulation also correlated with serum antidsDNA antibody concentrations (P ¼ 0.038, Fig. 5C ). The increase in frequencies of SmD1 83-119 -specific T-cells expressing IL-10 correlated with disease activity (P ¼ 0.006, Fig. 5D ), but not with serum antibody levels. 
Increase in frequencies of
Discussion
The analysis of the T-cell memory for cytokine expression, both systemic and autoantigen specific, may help to understand the role of autoreactive T-cells in SLE. Among the autoantigens that are known to be specifically recognized by the T-cells in SLE, the SmD1 83-119 peptide has been described as an important autoantigen in murine and human lupus [26, [28] [29] [30] . SmD1 83-119 -reactive T-cells have been identified and were associated with cardiopulmonary pathology in SLE patients [30] . Furthermore, SmD1
83-119 -reactive T-cells have been shown to provide T-cell help for pathogenic anti-dsDNA and anti-Sm antibodies in various murine lupus models [29] (manuscript in preparation).
Modulation of SmD1
83-119 -reactive T-cells by immunization or by induction of high-dose tolerance influences antidsDNA antibody levels and survival in murine lupus [11, 28] . Furthermore, similarities between both cultures can also reflect ongoing stimulations with autoantigens and, therefore, permanent activation and enrichment of autoreactive T-cells as it is suggested by studies showing the presence of nucleosomes in B-cell cultures [31] . One limitation of the approach used in the present study is that the in vitro enrichment of autoantigen specific T-cells might yield different cytokine producers than in vivo encounter of autoantigen in the specific lupus microenvironment. Here, we observed an increased cytokine memory for TNF-in cultures from SLE patients compared with those from healthy donors. Also, the frequencies of TNF--expressing memory T-cells correlated with disease activity. A role for TNF-þ Tcells in disease pathogenesis is also suggested by the frequencies of TNF-þ T-cells in the SmD1 83-119 driven ex vivo expansion in lupus patients. The higher the frequencies of memory T-cells expressing TNF-responding to the SmD1 83-119 peptide the higher were the anti-dsDNA antibody levels in the corresponding patient. Despite divergent results concerning the role of TNF-in lupus models [32, 33] , TNF-blockade has been successfully used in lupus patients suffering from nephritis [13] . Our results show that low frequencies of autoreactive TNF-þ memory T-cells correlate to clinical benefit in SLE. The association between levels of anti-SmD1 83-119 antibodies in serum and the frequencies of IFN-þ SmD1 -specific memory T-cells further underlines the importance of proinflammatory cytokines in SLE.
The cytokine memory for IL-10 was impaired in SLE. Frequencies of IL-10 expressing Th memory cells were decreased in the SmD1 83-119 -expanded Th cells of SLE patients compared with healthy donors. A reduced frequency of IL-10þ T-cells has been detected previously in SLE patients [34] , but their functional role in lupus pathogenesis remains unclear. Here, we show that this reduction is not only symptomatic but also affects autoreactive Th cells. Higher frequencies of SmD1 83-119 -specific memory Th cells expressing IL-10 were associated with low autoantibody levels in the supernatants. The data suggest an involvement of SmD1 -reactive IL-10 memory T-cells in the regulation of autoantibodies in SLE.
IL-10 appears to be a key cytokine in the pathogenesis of SLE since IL-10 polymorphisms are among the strongest susceptibility genetic factors in SLE [35] . This cytokine inhibits activation and effector function of antigen-presenting cells [36] . Thus, IL-10 has the potential to limit and terminate inflammatory immune reaction 37 including those of lupus. A beneficial effect of IL-10 is supported by studies in an experimental murine lupus model, showing a protective role of IL-10 [10, 11] .
Paradoxically, at first sight a pathogenetic role of IL-10 has also been postulated for lupus, based on the observation that systemic anti-IL-10 treatment is beneficial in murine and human lupus [38, 39] . This seemingly contradictory effect of IL-10 can be reconciled if one considers the source and time point of IL-10 production. IL-10 is expressed by various cells and IL-10 produced by non-T-cells appears to predominate [34] . While IL-10 producing T-cells may be protective by silencing Antigen Presenting Cell (APC) and Th1 cells as shown in in vitro studies [10, 11] , IL-10 derived from other cells may drive autoantibody production by B-cells. Furthermore, as shown in animal studies, the role of IL-10 is influenced by the stage of disease [10] . Late in disease development, an increasing frequency of IL-10-expressing T-cells directed to the autoantigens is required to suppress the ongoing autoimmune process. This possible defense mechanism is reflected here by the association between SmD1 83-119 -specific IL-10þ T-cells and disease activity as well as by our ongoing experiments in animal models showing a regulatoy function of IL-10 expressing autoreactive T-cells. During further progress of the disease, IL-10þ T-cells fail to suppress Th1 cells and APC efficiently, and consequently, IL-10 from Th cells and other cells augments differentiation of B-cells into plasma cells producing pathogenic autoreactive antibodies [10, 11] . This would explain both the previously described beneficial effect of anti-IL-10 on established and active disease and the protective effect of IL-10 on lupus aetiopathogenesis. It is to be shown, whether therapy with IL-10 memory Th cells may be superior to anti-IL-10 therapy as suggested by other groups in SLE [38, 39] 
